$15.90 Billion in Sales Expected for Humana Inc (NYSE:HUM) This Quarter

Wall Street analysts forecast that Humana Inc (NYSE:HUM) will post sales of $15.90 billion for the current fiscal quarter, according to Zacks. Six analysts have issued estimates for Humana’s earnings. The highest sales estimate is $15.97 billion and the lowest is $15.87 billion. Humana posted sales of $14.26 billion in the same quarter last year, which suggests a positive year over year growth rate of 11.5%. The company is scheduled to issue its next quarterly earnings results on Wednesday, August 7th.

On average, analysts expect that Humana will report full-year sales of $63.75 billion for the current year, with estimates ranging from $63.66 billion to $63.85 billion. For the next year, analysts expect that the company will post sales of $69.24 billion, with estimates ranging from $68.36 billion to $70.57 billion. Zacks’ sales averages are an average based on a survey of analysts that follow Humana.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, May 1st. The insurance provider reported $4.48 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $4.30 by $0.18. Humana had a net margin of 2.99% and a return on equity of 20.77%. The firm had revenue of $16.11 billion for the quarter, compared to analysts’ expectations of $15.67 billion. During the same quarter in the prior year, the business earned $3.36 EPS. The business’s quarterly revenue was up 12.8% on a year-over-year basis.

A number of research firms have commented on HUM. Zacks Investment Research cut shares of Humana from a “hold” rating to a “sell” rating in a research note on Thursday, April 11th. ValuEngine cut shares of Humana from a “hold” rating to a “sell” rating in a research note on Thursday, April 11th. Morgan Stanley set a $331.00 target price on shares of Humana and gave the stock a “buy” rating in a research note on Thursday, May 2nd. SunTrust Banks decreased their target price on shares of Humana to $300.00 in a research note on Thursday, May 2nd. Finally, Oppenheimer decreased their target price on shares of Humana from $373.00 to $350.00 and set an “outperform” rating on the stock in a research note on Thursday, May 2nd. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and fourteen have given a buy rating to the stock. Humana currently has an average rating of “Buy” and a consensus price target of $337.26.

A number of institutional investors and hedge funds have recently made changes to their positions in HUM. Morgan Stanley grew its holdings in Humana by 130.5% during the 3rd quarter. Morgan Stanley now owns 368,401 shares of the insurance provider’s stock valued at $124,712,000 after buying an additional 208,595 shares in the last quarter. Vanguard Group Inc grew its holdings in Humana by 1.4% during the 3rd quarter. Vanguard Group Inc now owns 10,104,225 shares of the insurance provider’s stock valued at $3,420,482,000 after buying an additional 140,864 shares in the last quarter. We Are One Seven LLC purchased a new stake in Humana during the 4th quarter valued at approximately $31,000. Keybank National Association OH grew its holdings in Humana by 1.7% during the 4th quarter. Keybank National Association OH now owns 2,259 shares of the insurance provider’s stock valued at $647,000 after buying an additional 37 shares in the last quarter. Finally, Gamco Investors INC. ET AL grew its holdings in Humana by 2.2% during the 4th quarter. Gamco Investors INC. ET AL now owns 6,583 shares of the insurance provider’s stock valued at $1,886,000 after buying an additional 140 shares in the last quarter. 92.63% of the stock is owned by institutional investors and hedge funds.

Shares of NYSE:HUM traded up $2.87 during trading on Wednesday, hitting $246.08. The company’s stock had a trading volume of 1,623,859 shares, compared to its average volume of 1,368,138. Humana has a 12 month low of $225.65 and a 12 month high of $355.88. The stock has a market capitalization of $33.61 billion, a PE ratio of 16.91, a price-to-earnings-growth ratio of 1.03 and a beta of 0.85. The company has a quick ratio of 1.65, a current ratio of 1.65 and a debt-to-equity ratio of 0.40.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be issued a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 0.89%. The ex-dividend date of this dividend is Thursday, June 27th. Humana’s dividend payout ratio (DPR) is currently 15.12%.

Humana Company Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Read More: How a Put Option Works

Get a free copy of the Zacks research report on Humana (HUM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.

 

$15.90 Billion in Sales Expected for Humana Inc (NYSE:HUM) This Quarter

Wall Street analysts forecast that Humana Inc (NYSE:HUM) will post sales of $15.90 billion for the current fiscal quarter, according to Zacks. Six analysts have issued estimates for Humana’s earnings. The highest sales estimate is $15.97 billion and the lowest is $15.87 billion. Humana posted sales of $14.26 billion in the same quarter last year, which suggests a positive year over year growth rate of 11.5%. The company is scheduled to issue its next quarterly earnings results on Wednesday, August 7th.

On average, analysts expect that Humana will report full-year sales of $63.75 billion for the current year, with estimates ranging from $63.66 billion to $63.85 billion. For the next year, analysts expect that the company will post sales of $69.24 billion, with estimates ranging from $68.36 billion to $70.57 billion. Zacks’ sales averages are an average based on a survey of analysts that follow Humana.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, May 1st. The insurance provider reported $4.48 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $4.30 by $0.18. Humana had a net margin of 2.99% and a return on equity of 20.77%. The firm had revenue of $16.11 billion for the quarter, compared to analysts’ expectations of $15.67 billion. During the same quarter in the prior year, the business earned $3.36 EPS. The business’s quarterly revenue was up 12.8% on a year-over-year basis.

A number of research firms have commented on HUM. Zacks Investment Research cut shares of Humana from a “hold” rating to a “sell” rating in a research note on Thursday, April 11th. ValuEngine cut shares of Humana from a “hold” rating to a “sell” rating in a research note on Thursday, April 11th. Morgan Stanley set a $331.00 target price on shares of Humana and gave the stock a “buy” rating in a research note on Thursday, May 2nd. SunTrust Banks decreased their target price on shares of Humana to $300.00 in a research note on Thursday, May 2nd. Finally, Oppenheimer decreased their target price on shares of Humana from $373.00 to $350.00 and set an “outperform” rating on the stock in a research note on Thursday, May 2nd. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and fourteen have given a buy rating to the stock. Humana currently has an average rating of “Buy” and a consensus price target of $337.26.

A number of institutional investors and hedge funds have recently made changes to their positions in HUM. Morgan Stanley grew its holdings in Humana by 130.5% during the 3rd quarter. Morgan Stanley now owns 368,401 shares of the insurance provider’s stock valued at $124,712,000 after buying an additional 208,595 shares in the last quarter. Vanguard Group Inc grew its holdings in Humana by 1.4% during the 3rd quarter. Vanguard Group Inc now owns 10,104,225 shares of the insurance provider’s stock valued at $3,420,482,000 after buying an additional 140,864 shares in the last quarter. We Are One Seven LLC purchased a new stake in Humana during the 4th quarter valued at approximately $31,000. Keybank National Association OH grew its holdings in Humana by 1.7% during the 4th quarter. Keybank National Association OH now owns 2,259 shares of the insurance provider’s stock valued at $647,000 after buying an additional 37 shares in the last quarter. Finally, Gamco Investors INC. ET AL grew its holdings in Humana by 2.2% during the 4th quarter. Gamco Investors INC. ET AL now owns 6,583 shares of the insurance provider’s stock valued at $1,886,000 after buying an additional 140 shares in the last quarter. 92.63% of the stock is owned by institutional investors and hedge funds.

Shares of NYSE:HUM traded up $2.87 during trading on Wednesday, hitting $246.08. The company’s stock had a trading volume of 1,623,859 shares, compared to its average volume of 1,368,138. Humana has a 12 month low of $225.65 and a 12 month high of $355.88. The stock has a market capitalization of $33.61 billion, a PE ratio of 16.91, a price-to-earnings-growth ratio of 1.03 and a beta of 0.85. The company has a quick ratio of 1.65, a current ratio of 1.65 and a debt-to-equity ratio of 0.40.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be issued a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 0.89%. The ex-dividend date of this dividend is Thursday, June 27th. Humana’s dividend payout ratio (DPR) is currently 15.12%.

Humana Company Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Read More: How a Put Option Works

Get a free copy of the Zacks research report on Humana (HUM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.